Arbeitsgruppe Neuroendokrine Tumoren/Karzinoide - Studien
Progressive pancreatic neuroendocrine neoplasms
AIO-assoziierte Studie
für weitere Zentren offen www.clinicaltrialsregister.eu zur Studie
AIO-NET-0117/ass: A multicenter single-arm pilot study of ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNet study)
--- in Rekrutierung ---
Neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET)
AIO-assoziierte Studie für weitere Zentren offen www.clinicaltrials.gov zur Studie
AIO-NET-0417/ass: A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR pos.), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).
 177Lu-edotreotide vs. everolimus in GEP-NET (COMPETE-Trial)
--- in Rekrutierung ---
LETZTE AKTUALISIERUNG DIESER SEITE AM: 06.12.2020